Altre lingue Endonovo Therapeutics, Inc.

Azioni

ENDV

US29272H3003

Mercato chiuso - OTC Markets Altri mercati azionari 18:30:42 03/05/2024			Variaz. 5gg	Var. 1 gen.
0,0025 ^USD	+25,94%		-3,85%	-71,26%

2023	Endonovo Therapeutics, Inc. riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 30 settembre 2023	CI
2023	Sofpulse® di Endonovo Therapeutics, Inc. ottiene l'approvazione della FDA di Taiwan	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc	28/03
Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions	04/03
Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/12
Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million	04/12
Endonovo's SofPulse® Secures Taiwan FDA Approval	12/10/23
Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval	12/10/23
Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution	22/08/23
Endonovo Therapeutics, Inc.'s SofPulse Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution	22/08/23
Endonovo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/08/23
Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update	08/08/23
New to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc.	22/06/23
Endonovo Pending Agreement to Develop Telehealth Division	07/06/23
Endonovo Therapeutics, Inc. Announces Pending Agreement to Develop Telehealth Division	07/06/23
Endonovo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	22/05/23
Endonovo Launches SofPulse® into the Veterans Administration	02/05/23
Endonovo Therapeutics, Inc. Launches SofPulse into the Veterans Administration	02/05/23
Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies	25/04/23
Endonovo Therapeutics, Inc. Announces Moving Forward in Its Clinical Development in the Field of Traumatic Brain Injury Treatment	25/04/23
ENDONOVO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	17/04/23
Endonovo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/04/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Endonovo Therapeutics, Inc.

Azioni

ENDV

US29272H3003

Altre lingue

Filtri